Advertisement


Anthony J. Olszanski, RPh, MD, on Immunotherapy and Melanoma

2015 NCCN Annual Conference

Advertisement

Anthony J. Olszanski, RPh, MD, of the Fox Chase Cancer Center, discusses the advances in immunotherapy generally and for melanoma in particular.



Related Videos

Gastroesophageal Cancer

Hans Gerdes, MD, on Endoscopic Therapies for Early-Stage Esophageal Cancers

Hans Gerdes, MD, of Memorial Sloan Kettering Cancer Center, discusses a new approach to the management of early-stage esophageal cancers with endoscopic resections.

Samuel M. Silver, MD, PhD, and Al B. Benson III, MD, FACP, FASCO, on 20 Years of Improving Cancer Care Together: A Clinical Perspective

Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Al B. Benson III, MD, FACP, FASCO, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the evolution of NCCN Guidelines, which are available free online,  and the components that make them effective: a multidisciplinary approach, the participation of patient advocates, consistency, and affordability of the evidence.

Survivorship

Rebecca H. Johnson, MD, on Fertility Preservation and Cancer

Although guidelines worldwide mandate fertility preservation for newly diagnosed patients within their reproductive window, most patients are still not referred or offered this option. Rebecca H. Johnson, MD, of Mary Bridge Children’s Hospital, explains the steps that need to be taken when counseling patients.

Colorectal Cancer

Axel Grothey, MD, on Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer

Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastatic colorectal cancer, individualizing patient care.

Lung Cancer

Thomas A. D’Amico, MD, on Diagnosis and Treatment of NSCLC Using Minimally Invasive Techniques

Thomas A. D’Amico, MD, of Duke Cancer Institute, discusses the superior efficacy of thoracoscopic lobectomy. This minimally invasive procedure is used in only 50% of lung cancer surgeries in the United States, in 30% of procedures in Asia, and in as few as 10% to 20% of procedures in Europe.

Advertisement

Advertisement




Advertisement